More than 700 nuclear medicine physicians, pharmacists, scientists, technologists, laboratory professionals, and industry partners from around the world gathered in Orlando, Florida, on February 1-3 for the SNMMI Mid-Winter and ACNM Annual Meeting.
Jeri Francoeur from Ormond Beach, Florida, has been elected to a two-year term as chair of SNMMI's Patient Advocacy Advisory Board.
On Tuesday, January 11, the Centers for Medicare and Medicaid Services (CMS) announced that it proposes to cover U.S. FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease under Coverage with Evidence Development in CMS-approved randomized controlled trials. Here is the SNMMI’s reaction.
Richard L. Wahl, MD, the Elizabeth E. Mallinckrodt Professor and head of radiology at Washington University School of Medicine in St. Louis, has been named 2021-22 president of the Society of Nuclear Medicine and Molecular Imaging.
Read More
The Society of Nuclear Medicine and Molecular Imaging named 17 new SNMMI Fellows during a plenary session at the society’s 2021 Annual Meeting, held virtually from June 11-15.
Read More
On June 7, the U.S. FDA approved aducanumab (Aduhelm) for the treatment of patients in the early stages of Alzheimer’s disease. Aducanumab selectively targets and removes beta amyloid plaques. SNMMI officials say they recognize the importance of this landmark approval, which was based on data from the ENGAGE trial.
Read More
SNMMI and 62 organizations, representing more than 1 million healthcare providers, thanked Congress for its past efforts on physician reimbursement and requested the inclusion of specific provisions in future legislation.
Read More
Last week, SNMMI and its partners strongly urged Congress to pass H.R. 1868 to extend the Medicare sequester moratorium through the end of 2021.
Read More